Quebec Biopharmaceutical Medicago and UK-based pharmaceutical company GlaxoSmithKline GSK,
Announced positive efficacy and safety results from a global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s epidemiological adjuvant, conducted in more than 24,000 subjects. The overall vaccine efficacy rate was 71% against all variants of SARS-COV-2. The vaccine candidate demonstrated an efficacy of 75.3% against COVID-19 of any severity for the globally dominant Delta variant, while the Omicron variant was not circulating during the study. During the study, no associated serious adverse events were reported and the reactogenicity was generally mild to moderate and transient, the companies said. Medicago, a unit of Mitsubishi Chemical 4188,
Will soon receive regulatory approval from Health Canada as part of its rolling submission.